Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate ionotropic receptor AMPA type subunit 1 (GluA1), encoded by the GRIA1 gene, is a core subunit of the ionotropic AMPA receptor (AMPAR) complex, which mediates the majority of fast excitatory neurotransmission in the mammalian brain (UniProt P42261). These receptors are tetrameric assemblies, and GluA1-containing AMPARs are particularly essential for the induction of long-term potentiation (LTP), a cellular mechanism fundamental to learning and memory (PubMed: 25414315). In pathological states, excessive activation of GluA1-containing receptors contributes to excitotoxicity and seizure activity in epilepsy, while their downregulation or dysfunction is linked to cognitive deficits in Alzheimer's disease and schizophrenia (PubMed: 30243539). Therapeutic strategies targeting GluA1 include non-competitive antagonists like perampanel, which is FDA-approved for epilepsy to reduce neuronal over-excitation (StatPearls: Perampanel). Additionally, positive allosteric modulators, known as AMPAkines, have been investigated for their potential to enhance cognitive function by prolonging the open-time of the ion channel (PubMed: 16116620). Safety concerns for drugs affecting this target often involve central nervous system side effects such as dizziness, ataxia, and potential behavioral changes (FDA Label: Fycompa). The target remains a high-interest area for neuropharmacology due to its central role in synaptic strength and plasticity.
Non-competitive or competitive antagonism to inhibit excitatory signaling, or positive allosteric modulation to enhance synaptic strength.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor AMPA type subunit 1 (GluA1) (GluA1).